Desflurane
ApprovedUNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Aortic Valve Stenosis
Conditions
Aortic Valve Stenosis
Trial Timeline
Jan 1, 2014 → Dec 1, 2016
NCT ID
NCT02019797About Desflurane
Desflurane is a approved stage product being developed by Baxter for Aortic Valve Stenosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT02019797. Target conditions include Aortic Valve Stenosis.
What happened to similar drugs?
5 of 13 similar drugs in Aortic Valve Stenosis were approved
Approved (5) Terminated (4) Active (6)
Hype Score Breakdown
Clinical
20
Activity
4
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02019797 | Approved | UNKNOWN |
Competing Products
20 competing products in Aortic Valve Stenosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Apixaban 5 MG + Apixaban 2.5 MG + Warfarin | Artivion | Phase 3 | 26 |
| Edoxaban | Daiichi Sankyo | Phase 3 | 36 |
| NOAC + DAPT | Daiichi Sankyo | Approved | 43 |
| Ticagrelor + Placebo | AstraZeneca | Phase 2 | 35 |
| Rosuvastatin + Placebo | AstraZeneca | Phase 3 | 40 |
| candesartan + placebo | AstraZeneca | Phase 3 | 36 |
| Sugammadex | Merck | Approved | 43 |
| bisoprolol + placebo | Merck | Approved | 35 |
| Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet | Merck | Phase 2/3 | 42 |
| Pelacarsen (TQJ230) 80mg + Matching placebo | Novartis | Phase 2 | 42 |
| fluvastatin | Novartis | Phase 2 | 31 |
| ACZ885 + Placebo | Novartis | Phase 2 | 27 |
| Evolocumab + Placebo | Amgen | Phase 1 | 36 |
| atorvastatin (Lipitor) | Pfizer | Approved | 35 |
| Apixaban + Standard of care | Pfizer | Phase 3 | 40 |
| Ataciguat + Placebo | Sanofi | Phase 1 | 29 |
| Ataciguat (HMR1766) | Sanofi | Phase 2 | 35 |
| Haemocomplettan® P + Saline solution | CSL | Phase 2 | 35 |
| Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA) | Bayer | Phase 3 | 29 |
| Acetylsalicylic acid + Clopidogrel + Rivaroxaban | Bayer | Phase 3 | 37 |